Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (KVUE) reports developments as a pure-play consumer health company with a brand portfolio that includes Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its updates center on consumer health categories, operating and financial results, and board actions such as cash dividends on common stock.
Recurring news themes also include material agreements, capital-structure matters, governance changes, shareholder voting topics and consumer-health regulatory disclosures. The coverage reflects Kenvue’s role as a public company operating branded everyday-care products across personal care, oral care, pain management and related health categories.
Kenvue (NYSE: KVUE) reported Q1 2026 results: net sales +4.5%, organic sales +0.7%, diluted EPS $0.25 (+47%), adjusted diluted EPS $0.32 (+33%). Gross margin expanded to 58.9% and adjusted gross margin to 60.8%. Operating margin widened to 19.6% and adjusted operating margin to 24.0%. Free cash flow rose to $0.4 billion. The company reaffirmed the expected close of its Kimberly-Clark transaction in H2 2026, subject to regulatory approvals, and disclosed a 2026 restructuring charge of about $250 million.
Kenvue (NYSE: KVUE) announced a quarterly cash dividend of $0.2075 per share. The dividend is payable on May 27, 2026 to shareholders of record at the close of business on May 13, 2026. Contact information for investor and media relations was provided.
Kenvue (NYSE: KVUE) will announce its first quarter 2026 financial results before market open on May 7, 2026. Due to a pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call.
The press release will be posted on the company's investor website at investors.kenvue.com. Investor and media contact emails are provided for follow-up.
Kimberly-Clark (NASDAQ: KMB) announced the post-closing organizational structure and named key leaders that will take effect after completing its pending acquisition of Kenvue, targeted to close in the second half of 2026. The combined company will operate four segments with estimated annual sales: North America $18.0B, EMEA $5.0B, Asia Pacific Focus Markets $4.3B, and Enterprise Markets $4.3B.
Mike Hsu will remain Chairman and CEO; a senior leadership roster and integration management office were disclosed to drive Day 1 readiness and identify growth and efficiency priorities.
Kenvue (NYSE:KVUE) reported Q4 2025 net sales +3.2% and organic sales +1.2%, with Q4 diluted EPS $0.17 and adjusted diluted EPS $0.27. Full year 2025 net sales declined 2.1% with diluted EPS $0.76 and adjusted diluted EPS $1.08. The company expects the Kimberly-Clark acquisition to close in H2 2026, subject to approvals.
Free cash flow rose to $1.7 billion and total debt was $8.5 billion as of December 28, 2025.
Kenvue (NYSE: KVUE) will report fourth quarter and full year 2025 results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call; the press release will be posted at the company investor website.
Investor and media contacts are provided for follow-up.
Kimberly-Clark (NASDAQ: KMB) and Kenvue (NYSE: KVUE) reported that shareholders at special meetings overwhelmingly approved the proposed acquisition of Kenvue by Kimberly-Clark.
Preliminary voting showed ~96% of shares at Kimberly-Clark approved issuance of Kimberly-Clark stock and ~99% of votes at Kenvue adopted the merger agreement (about 77% of outstanding Kenvue shares). The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on February 25, 2026 to shareholders of record at the close of business on February 11, 2026. This is a regular cash distribution on common stock.
The announcement lists investor and media contacts and describes Kenvue as a consumer health company with brands such as Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena and Tylenol.
Summary not available.
Kimberly-Clark (NASDAQ: KMB) agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock transaction valuing Kenvue at an enterprise value of approximately $48.7 billion (based on KMB close on Oct 31, 2025). The deal offers Kenvue shareholders $3.50 cash plus 0.14625 KMB shares (total $21.01 per KVUE share) and is expected to close in H2 2026, subject to approvals.
The combined company is projected to generate ~$32 billion revenue and ~$7 billion adjusted EBITDA in 2025, with anticipated run-rate synergies of $2.1 billion and $2.5 billion of one-time costs to capture them. Post-close ownership: ~54% KMB / 46% KVUE.